Vascular dementia Ppts and 196 Free Full Text articles

Vascular dementia is a decline in thinking skills caused by conditions that block or reduce blood flow to the brain, depriving brain cells of vital oxygen and nutrients.

Dementia
http://radiology.med.sc.edu

What is Dementia?
JEON, JOON-SEOK M.D.
http://www.pcom.edu/

Dementia: Diagnosis and Treatment
Debra L. Bynum, MD
http://www.med.unc.edu

Dementia & Delirium
http://www.med.unc.edu

Dementia Evaluation and Treatment
John Frederick MD
http://depts.washington.edu

The Facts about Dementia and Other Related Conditions
http://www.uwosh.edu

Behavior Vs. Medication Management
http://blogs.law.uiowa.edu

Dementia
Michael J. Mintzer, MD
http://www.medicine.emory.edu

Non-medication Management of Agitated Behavior in Dementia Patients
Josepha A. Cheong, MD
http://alzonline.phhp.ufl.edu

Memory impairment
Jack Twersky, MD
http://coegne.nursing.duke.edu

Cognitive Disorders
http://www.abac.edu

Neuroimaging of Alzheimer’s Disease
Kim Kinard
http://radiology.med.sc.edu

Managing rehabilitation challenges of patients with dementia
Tom Holmes, OTR, MA
http://www.uthct.edu


196 Free Full Text articles on Vascular dementia

1. Mulberry Fruit Extract Protects against Memory Impairment and Hippocampal Damage in Animal Model of Vascular Dementia.
2. Disturbed oscillatory brain dynamics in subcortical ischemic vascular dementia.
3. Genetics of subcortical vascular dementia.
4. Protein markers for the differential diagnosis of vascular dementia and Alzheimer's disease.
5. Apolipoprotein E gene polymorphism in a Chinese population with vascular dementia: a meta-analysis.
6. Lack of Association between Apolipoprotein E Polymorphism with Age at Onset of Subcortical Vascular Dementia.
7. Effect of vascular burden as measured by vascular indexes upon vascular dementia: a matched case-control study.
8. Systematic review on the efficacy and safety of herbal medicines for vascular dementia.
9. The central histamine level in rat model of vascular dementia.
10. Screening for new biomarkers for subcortical vascular dementia and Alzheimer's disease.
11. Effect of alcohol and tobacco use on vascular dementia: a matched case control study.
12. Vascular dementia.
13. Plasma 24S-hydroxycholesterol levels in elderly subjects with late onset Alzheimer's disease or vascular dementia: a case-control study.
14. Neurobiology of vascular dementia.
15. A voxel-based morphometric analysis of cerebral gray matter in subcortical ischemic vascular dementia patients and normal aged controls.
16. Magnetic resonance imaging-measured atrophy and its relationship to cognitive functioning in vascular dementia and Alzheimer's disease patients.
17. Depression in elderly patients with Alzheimer dementia or vascular dementia and its influence on their quality of life.
18. Gait and equilibrium in subcortical vascular dementia.
19. Drug discovery from Chinese medicine against neurodegeneration in Alzheimer's and vascular dementia.
20. A review of transcranial magnetic stimulation in vascular dementia.
21. The chinese (cantonese) montreal cognitive assessment in patients with subcortical ischemic vascular dementia.
22. Citicoline in vascular cognitive impairment and vascular dementia after stroke.
23. Episodes of Fall Asleep During Day Time in an Elder Woman with Vascular Dementia: Impact on Cerebral Ischeamic Tolerance and Utility of ECG Holter Monitoring.
24. Genetic evidence that vascular dementia is related to Alzheimer's disease: genetic association between tau polymorphism and vascular dementia in the Chinese population.
25. Progression of vascular depression to possible vascular dementia.
26. Toward a pathological definition of vascular dementia.
27. CSF Biomarkers Profile in CADASIL-A Model of Pure Vascular Dementia: Usefulness in Differential Diagnosis in the Dementia Disorder.
28. Hippocampal morphometry in population-based incident Alzheimer's disease and vascular dementia: the HAAS.
29. Predictors of the progression of dementia severity in brazilian patients with Alzheimer's disease and vascular dementia.
30. [Effects of moxibustion at head-points on levels of somatostatin and arginine vasopressin from cerebrospinal fluid in patients with vascular dementia: a randomized controlled trial].
31. [Effect of Shengmaisan on learning and memory abilities and hippocampal nitric oxide synthase expression and neuronal apoptosis in rats with vascular dementia].
32. Limitations in differentiating vascular dementia from Alzheimer's disease with brief cognitive tests.
33. A mouse model characterizing features of vascular dementia with hippocampal atrophy.
34. Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size.
35. Association between APOE epsilon4 allele and vascular dementia: The Cache County study.
36. Hemostasis and vascular dementia.
37. Arterioles in cerebral amyloid angiopathy and vascular dementia.
38. Quantification of myelin loss in frontal lobe white matter in vascular dementia, Alzheimer's disease, and dementia with Lewy bodies.
39. Cancer linked to Alzheimer disease but not vascular dementia.
40. Imaging cerebral microbleeds using susceptibility weighted imaging: one step toward detecting vascular dementia.
41. Cerebral blood flow in ischemic vascular dementia and Alzheimer's disease, measured by arterial spin-labeling magnetic resonance imaging.
42. Pathophysiology of vascular dementia.
43. The potential for estrogens in preventing Alzheimer's disease and vascular dementia.
44. [Effects of Ruanmailing Oral Liquid on spatial learning and memory ability and expression of APE/Ref-1 in hippocampal CA1 region in rats with experimental vascular dementia].
45. Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later.
46. Increased plasma urotensin-II and carotid atherosclerosis are associated with vascular dementia.
47. Cholinergic deficiency involved in vascular dementia: possible mechanism and strategy of treatment.
48. Absence of MRI exams in epidemiological studies can leads to clinical overdiagnosis of Alzheimer's disease and underdiagnosis of vascular dementia.
49. Lack of association between PRNP 1368 polymorphism and Alzheimer's disease or vascular dementia.
50. Progression to vascular dementia of patients with mild cognitive impairment: relevance of mild parkinsonian signs.
51. The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged.
52. Regional white matter integrity differentiates between vascular dementia and Alzheimer disease.
53. Metabolic syndrome and risk for incident Alzheimer's disease or vascular dementia: the Three-City Study.
54. Serum copper in Alzheimer's disease and vascular dementia.
55. Vascular compliance is reduced in vascular dementia and not in Alzheimer's disease.
56. Ameliorative role of Atorvastatin and Pitavastatin in L-Methionine induced vascular dementia in rats.
57. Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors.
58. [Therapeutic effects of scalp-acupuncture in patients with vascular dementia induced by cerebral infarction: a randomized controlled trial].
59. Vascular dementia by thalamic strategic infarct.
60. Cerebral arachidonate cascade in dementia: Alzheimer's disease and vascular dementia.
61. Risk factors for vascular dementia: hypotension as a key point.
62. Free and cued selective reminding distinguishes Alzheimer's disease from vascular dementia.
63. Diagnostic criteria of vascular dementia in CADASIL.
64. [Features differentiating comorbidity in elderly patients with Alzheimer-type dementia or with vascular dementia].
65. Neurological signs in relation to type of cerebrovascular disease in vascular dementia.
66. Vascular dementia: prevention and treatment.
67. Rivastigmine in Chinese patients with subcortical vascular dementia.
68. Vascular dementia: pharmacological treatment approaches and perspectives.
69. [Effect of Naoxintong capsules on calcitonin gene-related peptide of vascular dementia in rats].
70. The contribution of medial temporal lobe atrophy and vascular pathology to cognitive impairment in vascular dementia.
71. Influence of galantamine on vasomotor reactivity in Alzheimer's disease and vascular dementia due to cerebral microangiopathy.
72. Immunohistochemical study of N-epsilon-carboxymethyl lysine (CML) in human brain: relation to vascular dementia.
73. Subcortical ischemic vascular dementia.
74. Clinical significance of microbleeds in subcortical vascular dementia.
75. Risk factors for vascular dementia: a hospital-based study in Taiwan.
76. Vascular dementia in leukoaraiosis may be a consequence of capillary loss not only in the lesions, but in normal-appearing white matter and cortex as well.
77. The gene encoding transforming growth factor beta 1 confers risk of ischemic stroke and vascular dementia.
78. Protective effects of breviscapine on ischemic vascular dementia in rats.
79. Endovascular middle cerebral artery occlusion in rats as a model for studying vascular dementia.
80. Cognitive predictors of functional decline in vascular dementia.
81. Visual association memory test in differentiating early stage of Alzheimer's disease from vascular dementia.
82. [18FDG PET cerebral function imaging in 10 vascular dementia patients receiving needling at Baihui(DU20), Shuigou(DU26) and Shenmen(HT7)].
83. [Glutamate-related excitotoxicity neuroprotection with memantine, an uncompetitive antagonist of NMDA-glutamate receptor, in Alzheimer's disease and vascular dementia].
84. Efficacy study of galantamine in possible Alzheimer's disease with or without cerebrovascular disease and vascular dementia in Thai patients: a slow-titration regimen.
85. Cerebral emboli as a potential cause of Alzheimer's disease and vascular dementia: case-control study.
86. Small vessel disease and subcortical vascular dementia.
87. Vascular dementia may be easier to treat than diagnose.
88. Infratentorial abnormalities in vascular dementia.
89. [Effects of needling in Baihui (DU20), Shuigou (DU26) and Shenmen (HT7) on glucose metabolism in the lentiform nucleus in patients with vascular dementia].
90. Research into the treatment of vascular dementia in China using traditional therapies.
91. Lacunes and vascular dementia.
92. Fibrinogen is associated with an increased risk of Alzheimer disease and vascular dementia.
93. [An update on the diagnosis of vascular dementia].
94. The Closing-in Phenomenon in Alzheimer's Disease and Vascular Dementia.
95. Neuropsychiatric profiles in patients with Alzheimer's disease and vascular dementia.
96. Subcortical vascular dementia: integrating neuropsychological and neuroradiologic data.
97. [Vascular dementia: the dubious disease].
98. Correlates of hippocampal neuron number in Alzheimer's disease and ischemic vascular dementia.
99. Determinants of vascular dementia in the Cardiovascular Health Cognition Study.
100. Assessment and prediction of functional impairment in vascular dementia.
101. Efficacy and safety of nimodipine in subcortical vascular dementia: a randomized placebo-controlled trial.
102. Donepezil in the treatment of vascular dementia.
103. Lack of association between vascular dementia and Chlamydia pneumoniae infection: a case-control study.
104. Risk factors for vascular dementia and Alzheimer disease.
105. Differential acetylcholine and choline concentrations in the cerebrospinal fluid of patients with Alzheimer's disease and vascular dementia.
106. Deterioration of vascular dementia caused by recurrent multiple small emboli from thoracic aortic atheroma.
107. Homocysteine, folate, and vitamin B-12 in mild cognitive impairment, Alzheimer disease, and vascular dementia.
108. Cognitive functioning in preclinical vascular dementia: a 6-year follow-up.
109. Relation of plasma lipids to Alzheimer disease and vascular dementia.
110. [Vascular dementia--an ill-defined concept].
111. Measurement of gelatinase B (MMP-9) in the cerebrospinal fluid of patients with vascular dementia and Alzheimer disease.
112. Emerging therapies for vascular dementia and vascular cognitive impairment.
113. "Closing-in" phenomenon in Alzheimer's disease and subcortical vascular dementia.
114. Thalamic lesions in vascular dementia: low sensitivity of fluid-attenuated inversion recovery (FLAIR) imaging.
115. Distinctive cognitive profiles in Alzheimer's disease and subcortical vascular dementia.
116. Neurosteroids: Cerebrospinal fluid levels for Alzheimer's disease and vascular dementia diagnostics.
117. Editorial comment--How to treat vascular dementia?
118. Clinical and neuroimaging correlates of abnormal short-latency Somatosensory Evoked Potentials in elderly vascular dementia patients: A psychophysiological exploratory study.
119. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial.
120. Nicotinic acetylcholine receptor distribution in Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease, and vascular dementia: in vitro binding study using 5-[(125)i]-a-85380.
121. Heterogeneity of cerebral blood flow in Alzheimer disease and vascular dementia.
122. Different patterns of N-acetylaspartate loss in subcortical ischemic vascular dementia and AD.
123. Prospective Belgian study of neurodegenerative and vascular dementia: APOE genotype effects.
124. Operational definitions for the NINDS-AIREN criteria for vascular dementia: an interobserver study.
125. Association of apolipoprotein E polymorphism in late-onset Alzheimer's disease and vascular dementia in Brazilians.
126. [A case of brittle diabetes in a 94-year-old man with vascular dementia, visual disturbance and hearing difficulty].
127. Statistical image analysis of cerebral blood flow in vascular dementia with small-vessel disease.
128. Is the distinction between Alzheimer's disease and vascular dementia possible and relevant?
129. Acetylcholinesterase inhibitors for vascular dementia and Alzheimer's disease combined with cerebrovascular disease.
130. Vascular dementia.
131. Moderately elevated plasma homocysteine, methylenetetrahydrofolate reductase genotype, and risk for stroke, vascular dementia, and Alzheimer disease in Northern Ireland.
132. Is mild cognitive impairment prodromal for vascular dementia like Alzheimer's disease?
133. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).
134. Effects of subcortical ischemic vascular dementia and AD on entorhinal cortex and hippocampus.
135. Patients with vascular dementia due to microvascular pathology have significant hippocampal neuronal loss.
136. Diagnosis of vascular dementia.
137. Volumetric MRI study of the caudate nucleus in patients with dementia with Lewy bodies, Alzheimer's disease, and vascular dementia.
138. Vascular dementia: a diagnosis running out of time.
139. Lipoprotein profile in older patients with vascular dementia and Alzheimer's disease.
140. Plasma somatostatin and gastrointestinal peptides in Alzheimer's disease and vascular dementia.
141. White matter damage is associated with matrix metalloproteinases in vascular dementia.
142. [Clinical significance of white matter lesion in vascular dementia].
143. [Clinical characterization of vascular dementia: retrospective evaluation of an outpatient sample].
144. [Vascular dementia].
145. Magnetization transfer measurements of the hippocampus in patients with Alzheimer's disease, vascular dementia, and other types of dementia.
146. Pathogenicity of thermolabile methylenetetrahydrofolate reductase for vascular dementia.
147. Vascular dementia : incidence and risk factors in the Canadian study of health and aging.
148. Allopregnanolone and dehydroepiandrosterone response to corticotropin-releasing factor in patients suffering from Alzheimer's disease and vascular dementia.
149. Subcortical ischemic vascular dementia: assessment with quantitative MR imaging and 1H MR spectroscopy.
150. Comparison of different clinical criteria (DSM-III, ADDTC, ICD-10, NINDS-AIREN, DSM-IV) for the diagnosis of vascular dementia. National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et l'Enseignement en Neurosciences.
151. [A follow-up study on the outcome and relevant factors in senile dementia of Alzheimer type and vascular dementia].
152. White matter lesions on magnetic resonance imaging in dementia with Lewy bodies, Alzheimer's disease, vascular dementia, and normal aging.
153. Magnetization transfer ratio of white matter hyperintensities in subcortical ischemic vascular dementia.
154. Effect of thrombin inhibition in vascular dementia and silent cerebrovascular disease. An MR spectroscopy study.
155. Plasma chain-breaking antioxidants in Alzheimer's disease, vascular dementia and Parkinson's disease.
156. [Treatments for vascular dementia and Alzheimer's disease].
157. Spatz-Lindenberg disease: a rare cause of vascular dementia.
158. Neuropathological assessment of the lesions of significance in vascular dementia.
159. Death certification in treated cases of presenile Alzheimer's disease and vascular dementia in Scotland.
160. Clinical overdiagnosis of vascular dementia versus necropsy confirmed series.
161. The Canadian Study of Health and Aging: risk factors for vascular dementia.
162. Diagnostic criteria for vascular dementia.
163. From UBOs to Binswanger's disease. Impact of magnetic resonance imaging on vascular dementia research.
164. Cognitive decline in patients with Alzheimer's disease, vascular dementia and senile dementia of Lewy body type.
165. [Problems in vascular dementia].
166. Neuropsychological, psychiatric, and cerebral blood flow findings in vascular dementia and Alzheimer's disease.
167. Regional gray and white matter metabolite differences in subjects with AD, with subcortical ischemic vascular dementia, and elderly controls with 1H magnetic resonance spectroscopic imaging.
168. Alzheimer disease and subcortical ischemic vascular dementia: evaluation by combining MR imaging segmentation and H-1 MR spectroscopic imaging.
169. Vascular dementia.
170. The diagnosis of vascular dementia in the light of the new criteria.
171. Comparison of different diagnostic criteria for vascular dementia (ADDTC, DSM-IV, ICD-10, NINDS-AIREN).
172. H-1 MR spectroscopic imaging of white matter signal hyperintensities: Alzheimer disease and ischemic vascular dementia.
173. Education and prevalence of Alzheimer's disease and vascular dementia. A study of patients living in institutes may bias the findings.
174. Education and prevalence of Alzheimer's disease and vascular dementia. Premorbid ability influences measures used to identify dementia.
175. Neural-network-based classification of cognitively normal, demented, Alzheimer disease and vascular dementia from single photon emission with computed tomography image data from brain.
176. Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam study.
177. Apolipoprotein E polymorphism in Japanese patients with Alzheimer's disease or vascular dementia.
178. [Relationship between behavioral problems and cognitive status in Alzheimer type and mixed Alzheimer and vascular dementia].
179. Serum autoantibodies in patients with Alzheimer's disease and vascular dementia and in nondemented control subjects.
180. Cerebrovascular responsiveness to hypercapnia in Alzheimer's dementia and vascular dementia of the Binswanger type.
181. Medical disorders in Alzheimer's disease and vascular dementia.
182. Leukoaraiosis correlates with cerebral hypoperfusion in vascular dementia.
183. Twenty-four-hour variation of blood pressure in vascular dementia of the Binswanger type.
184. Cerebral blood flow and oxygen metabolism in patients with vascular dementia of the Binswanger type.
185. The decline and resurgence of vascular dementia.
186. [Hematocrit, serum lipids and cardiovascular indices as risk factors in vascular dementia].
187. [Evaluation of the cerebral lesion and perfusion as risk factors in vascular dementia].
188. Accuracy of the clinical diagnosis of vascular dementia: a prospective clinical and post-mortem neuropathological study.
189. [The effects of cerebral vasodilators and stimulators of brain metabolism on the patients with vascular dementia].
190. [On pathogenesis of vascular dementia].
191. Do white matter changes on MRI and CT differentiate vascular dementia from Alzheimer's disease?
192. Do white matter changes on MRI and CT differentiate vascular dementia from Alzheimer's disease?
193. Short-latency somatosensory evoked potentials in degenerative and vascular dementia.
194. Diagnostic evaluation of degenerative and vascular dementia.
195. Vascular dementia--still overdiagnosed.
196. Electroencephalography and computerised tomography in vascular and non-vascular dementia in old age.